• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于肺泡给药的聚乳酸-羟基乙酸共聚物(PLGA)、壳聚糖或壳聚糖包被的PLGA微粒?雾化过程中颗粒稳定性的比较研究。

PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization.

作者信息

Manca Maria-Letizia, Mourtas Spyridon, Dracopoulos Vassileios, Fadda Anna Maria, Antimisiaris Sophia G

机构信息

Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26510, Greece.

出版信息

Colloids Surf B Biointerfaces. 2008 Apr 1;62(2):220-31. doi: 10.1016/j.colsurfb.2007.10.005. Epub 2007 Oct 11.

DOI:10.1016/j.colsurfb.2007.10.005
PMID:18023977
Abstract

Various types of rifampicin (RIF)-loaded microparticles were compared for their stability during nebulization. Poly(lactide-co-glycolide) (PLGA), chitosan (CHT) and PLGA/CHT microparticles (MPs) were prepared by emulsion or precipitation techniques. MPs ability to be nebulized (NE%) as well as stability during freeze-drying or/and nebulization (NEED%), were evaluated after RIF extraction from MPs and determination by light spectroscopy. MP mean diameters and zeta-potential values were measured by dynamic light scattering, morphology was assessed by SEM, cytotoxicity by MTT method and mucoadhesive properties by mucin association. In all cases, freeze-drying prior to nebulization did not affect EE%, NE or NEED%. In CHT, MPs RIF encapsulation efficiency (EE%) decreased with increasing CHT concentration (viscosity) and CHT-MP NEED% was higher when the polymer was crosslinked by glutaraldehyde. PLGA MPs, exhibited both higher RIF EE% and also higher nebulization ability and NEED%, compared to CHT ones, but also higher cytotoxicity. However, when the two polymers were combined in the PLGA/CHT MPs, EE%, NE% and NEED% increased with increasing MP CHT-content. PLGA/CHT MPs with 0.50% or 0.75% CHT exhibited highest EE% for RIF and also best nebulization ability and stability, compared to all other MP formulations studied. Additionally they had good mucoadhesive properties and comparably low cytotoxicity.

摘要

比较了各种负载利福平(RIF)的微粒在雾化过程中的稳定性。通过乳液或沉淀技术制备了聚(丙交酯-共-乙交酯)(PLGA)、壳聚糖(CHT)和PLGA/CHT微粒(MPs)。从MPs中提取RIF并通过光谱法测定后,评估了MPs的雾化能力(NE%)以及冻干或/和雾化过程中的稳定性(NEED%)。通过动态光散射测量MPs的平均直径和zeta电位值,通过扫描电子显微镜评估形态,通过MTT法评估细胞毒性,通过与粘蛋白结合评估粘膜粘附特性。在所有情况下,雾化前的冻干均不影响包封率(EE%)、NE或NEED%。在CHT中,MPs的RIF包封率(EE%)随着CHT浓度(粘度)的增加而降低,当聚合物用戊二醛交联时,CHT-MP的NEED%更高。与CHT微粒相比,PLGA微粒表现出更高的RIF EE%、更高的雾化能力和NEED%,但细胞毒性也更高。然而,当两种聚合物在PLGA/CHT MPs中组合时,EE%、NE%和NEED%随着MP CHT含量的增加而增加。与所有其他研究的MP制剂相比,含有0.50%或0.75% CHT的PLGA/CHT MPs对RIF表现出最高的EE%,以及最佳的雾化能力和稳定性。此外,它们具有良好的粘膜粘附特性和相对较低的细胞毒性。

相似文献

1
PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery? A comparative study of particle stability during nebulization.用于肺泡给药的聚乳酸-羟基乙酸共聚物(PLGA)、壳聚糖或壳聚糖包被的PLGA微粒?雾化过程中颗粒稳定性的比较研究。
Colloids Surf B Biointerfaces. 2008 Apr 1;62(2):220-31. doi: 10.1016/j.colsurfb.2007.10.005. Epub 2007 Oct 11.
2
Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles.利福平从壳聚糖、聚乳酸-羟基乙酸共聚物及壳聚糖包衣的聚乳酸-羟基乙酸共聚物微粒中的释放。
Colloids Surf B Biointerfaces. 2008 Dec 1;67(2):166-70. doi: 10.1016/j.colsurfb.2008.08.010. Epub 2008 Aug 22.
3
Liposomes for drug delivery to the lungs by nebulization.用于通过雾化将药物递送至肺部的脂质体。
Eur J Pharm Biopharm. 2007 Nov;67(3):655-66. doi: 10.1016/j.ejpb.2007.04.005. Epub 2007 Apr 18.
4
Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery.载利福平 PLGA 微球的制备及其体外特性考察-用于肺部的持续释放。
Int J Pharm. 2011 Jul 29;414(1-2):112-7. doi: 10.1016/j.ijpharm.2011.05.007. Epub 2011 May 10.
5
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model.含利福平的可吸入聚乳酸-羟基乙酸共聚物微球用于治疗结核病:在传染病模型中的筛选
Pharm Res. 2001 Sep;18(9):1315-9. doi: 10.1023/a:1013094112861.
6
Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin.使用载有利福平的聚乳酸-羟基乙酸共聚物(PLGA)微球将利福平高效细胞内递送至肺泡巨噬细胞:PLGA的分子量和组成对利福平释放的影响
Colloids Surf B Biointerfaces. 2004 Jul 1;36(1):35-42. doi: 10.1016/j.colsurfb.2004.03.018.
7
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.使用四流体喷嘴喷雾干燥器一步制备含利福平/聚乳酸-羟基乙酸共聚物纳米颗粒的甘露醇微球用于肺结核吸入治疗
J Control Release. 2009 Apr 2;135(1):19-24. doi: 10.1016/j.jconrel.2008.11.027. Epub 2008 Dec 7.
8
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.用于实验性结核病的基于聚(DL-丙交酯-共-乙交酯)纳米颗粒的可吸入持续给药系统
J Antimicrob Chemother. 2003 Dec;52(6):981-6. doi: 10.1093/jac/dkg477. Epub 2003 Nov 12.
9
Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions.壳聚糖表面修饰的聚乳酸-羟基乙酸共聚物纳米球通过粘膜粘附和细胞间紧密连接的开放改善了降钙素的肺部递送。
J Control Release. 2005 Feb 2;102(2):373-81. doi: 10.1016/j.jconrel.2004.10.010.
10
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.用于治疗结核病的含利福平的可吸入性聚乳酸-羟基乙酸共聚物微球:制备与表征
Pharm Res. 2000 Aug;17(8):955-61. doi: 10.1023/a:1007527204887.

引用本文的文献

1
Modified-Release Pulmonary Delivery Systems for Labile Bioactives: Design, Development, and Applications.用于不稳定生物活性物质的缓释肺部给药系统:设计、开发与应用
Pharmaceutics. 2025 Apr 3;17(4):470. doi: 10.3390/pharmaceutics17040470.
2
Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics.口服载多西他赛的壳聚糖修饰阳离子聚乳酸-羟基乙酸共聚物纳米粒用于肠道肿瘤:制剂、全面的体外表征及释放动力学
Beilstein J Nanotechnol. 2022 Nov 23;13:1393-1407. doi: 10.3762/bjnano.13.115. eCollection 2022.
3
Chitosan/poly(lactic-co-glycolic)acid Nanoparticle Formulations with Finely-Tuned Size Distributions for Enhanced Mucoadhesion.
具有精细调节尺寸分布以增强粘膜粘附性的壳聚糖/聚(乳酸-共-乙醇酸)纳米颗粒制剂
Pharmaceutics. 2022 Jan 1;14(1):95. doi: 10.3390/pharmaceutics14010095.
4
Novel technique of insulin loading into porous carriers for oral delivery.用于口服给药的胰岛素载入多孔载体的新技术。
Asian J Pharm Sci. 2018 Jul;13(4):297-309. doi: 10.1016/j.ajps.2018.03.003. Epub 2018 Apr 17.
5
Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.纳米药物作为抗结核药物的药物递送载体:从发病机制到感染控制。
Curr Drug Deliv. 2019;16(5):400-429. doi: 10.2174/1567201816666190201144815.
6
Role of Nitric Oxide-Releasing Chitosan Oligosaccharides on Mucus Viscoelasticity.释放一氧化氮的壳寡糖对黏液黏弹性的作用
ACS Biomater Sci Eng. 2017;3(6):1017-1026. doi: 10.1021/acsbiomaterials.7b00039. Epub 2017 May 15.
7
Targeted Delivery of GP5 Antigen of PRRSV to M Cells Enhances the Antigen-Specific Systemic and Mucosal Immune Responses.PRRSV 的 GP5 抗原靶向递送至 M 细胞增强了抗原特异性的系统和黏膜免疫应答。
Front Cell Infect Microbiol. 2018 Jan 25;8:7. doi: 10.3389/fcimb.2018.00007. eCollection 2018.
8
Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy.整合素靶向 PLGA-壳聚糖纳米粒递药用于肺癌治疗。
Sci Rep. 2017 Nov 7;7(1):14674. doi: 10.1038/s41598-017-15012-5.
9
Polymeric nanoparticles for pulmonary protein and DNA delivery.聚合物纳米粒用于肺部蛋白和 DNA 的递送。
Acta Biomater. 2014 Jun;10(6):2643-52. doi: 10.1016/j.actbio.2014.01.033. Epub 2014 Feb 8.
10
Composition influence on pulmonary delivery of rifampicin liposomes.组成对利福平脂质体肺部递药的影响。
Pharmaceutics. 2012 Nov 27;4(4):590-606. doi: 10.3390/pharmaceutics4040590.